Esophageal Cancer (Squamous Cell)

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    EGFR Mutation 19% Gefitinib (EGFR TKI):
    • Phase 2: OS 3.7 vs. 3.6 mo with placebo (1)
    Afatinib (EGFR TKI):
    • Phase 2: ORR 14.3%, DCR 73.3%, OS 6.6 mo (2)
    EGFR Overexpression 30%–90% Panitumumab (EGFR inhibitor):
    • Phase 3: Trial was stopped at interim futility analysis (3)
    PI3K Mutation PI3KCA 13% BKM120 (PI3K inhibitor)
    • Phase 2: DCR 51.2%, mOS 9.0 mo (4)
    PD-1 Overexpression PD-L1/PD-L2 43.9% (5) Nivolumab (PD-1 inhibitor)*:
    • Phase 2: ORR 17%, DCR 42%, mOS 10.8 mo
    Other topics in Targets by Organ Site